Gene Therapy for Muscular Dystrophy Faces Safety Concerns After Second Fatality
TL;DR
Sarepta Therapeutics' gene therapy for muscular dystrophy, Elevidys, faced scrutiny after reports of a second death linked to acute liver injury, leading to a pause in treatment for older patients and a significant drop in stock prices, with potential regulatory implications.
- Second patient death reported with gene therapy for muscular dystrophy Yahoo Finance
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Sarepta Therapeutics
- After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry statnews.com
- Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures WSJ
- Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug Investopedia
Want the full story? Read the original reporting
Read on Yahoo Finance